

REMARKS

Status of the Claims

Claims 1-4, 6-10, 15, 16 and 20-22 were pending.

Claims 1-4, 6-10, 15, 16 and 20-22 have been rejected under 35 U.S.C. 112, first and second paragraphs.

Claims 2 and 3 are canceled in this amendment.

Amendment of the Specification

In response to the new matter rejection the Specification has been amended to reinstate the paragraphs on page 5 lines 14-29; page 15, lines 3-18; and page 25, lines 17-32 as originally filed.

Applicants believe that the present amendments made to the Specification and Claims do not add new matter, nor do they broaden the scope of what is claimed.

Rejections maintained from Office Action mailed March 15, 2006

The Examiner contends that the correction of the typographical error, namely the correction of “-T¹²N(R¹⁶)-T¹⁵-T¹⁰” to “-T¹²N(R¹⁶)-T¹³-T¹⁰” in the definition of T¹⁻⁹ in claims 1 and 6 amounts to new matter. Accordingly, the corrected variable “-T¹²N(R¹⁶)-T¹³-T¹⁰” has been removed from claims 1 and 6, and the original paragraph containing this variable has been reinstated into the specification (see above section). As a necessary consequence (lack of antecedent basis):

- 1) “-NHCH₂CH₂NHC(O)CH₃” and 3-CH₃C(O)NHpyrrolidiny-1-yl” have been deleted from the Z variable of dependent claim 7; and
- 2) 4-CH₃CH₂SO₂NHbenzyl, 4-CH₃SO₂NHC(=O)benzyl, 4-CH₃CH₂CH₂SO₂NHbenzyl, -4-(CH₃)₂CHSO₂NHbenzyl, and 4-CH₃CH₂SO₂NHbenzyl have been deleted from the R₅ definition of dependent claim 8.

Also, the Examiner continued to reject the limitation “haloalkyl” in the definition of Y⁵ of claim 3 as Applicants mistakenly instead deleted this limitation from variables Y² and Y³ in the last amendment. Accordingly, in this amendment the limitation, “haloalkyl” has been deleted from the definition of R⁵ in claim 3 (the substance of which has been incorporated into claim 1 and claim 3 canceled), and the limitation “haloalkyl” was reinstated into the definition of Y₂ and Y₃.

New Rejections under 35 U.S.C. 112

The Examiner has newly rejected the claims for failure to comply with written description contending that T¹¹ and -NHS(O)_t(T¹¹) in the definition of R⁷ and “-T¹²N(R¹⁶)-T¹³-T¹⁰” in the

definition of T^1 - T^9 (subparagraphs i. and ii.) are not defined in claim 1. Also, the Examiner claims the haloalkyl moiety in the definition of T^{10} of claim 6 and claim 22 is new matter. In response, all the aforementioned variables have been deleted from the afore-described definitions.

Also, Claims 1-4, 6-10, 15, 16 and 20-22 have been rejected under 35 U.S.C. 112, second paragraph as being indefinite for a) inappropriate periods in R^{20} and R^{21} of Claim 1, b) the second occurrence of T^1 - T^9 in claim 6, c) & f) the second occurrence of 4-NH₂C(=O)-benzyl moiety in claims 8 and 22, d) & e) periods after subparagraphs in claims 16 and 21, and g) lack of the definition of "t" and " T^{11} " in claim 22.

In response, Applicants have replaced the period in the definition of R^{20} and R^{21} of claim 1 and in the subparagraph of claims 16 and 21 with closed parentheses. Also, the second occurrence of T^1 - T^9 in claim 6 has been deleted as well as the second occurrence of 4-NH₂C(=O)-benzyl moiety in claims 8 and 22. Finally, the definition of "t" has been added to claim 22 (basis for the addition can be found in original claim 6) and the variable containing T^{11} ($--S(O)_tN(T^{11})T^{22}$) has been deleted from the definition of T^{15} in claim 22.

In summary, Applicants believe all the rejections of the claims under 35 USC 112, first and second paragraphs, have been either addressed or rendered moot. Applicants respectfully request withdrawal of the written description and indefiniteness rejections and believe the claims are now in condition for allowance.


FEES

No fee should be due, however, if it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323


Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096

Date: November 30, 2006